Conference Roundup

Positive interim RGX-314 data on RGX-314 for diabetic retinopathy announced

REGENXBIO Inc today announced additional positive interim data from the ongoing phase 2 ALTITUDE trial of RGX-314 for the treatment of diabetic retinopathy (DR) without center-involved diabetic macular edema (CI-DME) using in-office suprachoroidal delivery. The data were presented at the 55th Annual Retina Society meeting. RGX-314 is being investigated as...